What's in Stemform's pipeline?

Stemform has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Stemform's portfolio?

Top competitors by shared drug class: American University of Beirut Medical Center, Kuhnil Pharmaceutical Co., Ltd., Taejoon Pharmaceutical Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stemform.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Stemform — Portfolio Competitive Intelligence Brief

Stemform pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ASC enriched lipofilling	ASC enriched lipofilling	phase 3	Cell therapy / Regenerative medicine		Regenerative Medicine / Plastic and Reconstructive Surgery
Standard Lipofilling	Standard Lipofilling	phase 3			Regenerative Medicine / Aesthetics

Therapeutic area mix

Regenerative Medicine / Aesthetics · 1
Regenerative Medicine / Plastic and Reconstructive Surgery · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

American University of Beirut Medical Center · 1 shared drug class
Kuhnil Pharmaceutical Co., Ltd. · 1 shared drug class
Taejoon Pharmaceutical Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stemform:

Cite this brief

Drug Landscape (2026). Stemform — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stemform. Accessed 2026-05-14.